Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy

Abstract

Purpose: To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC).

Methods: This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC.

Results: Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity.

Conclusions: Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.